17646-08-1

Basic information

• Product Name: 2-Brom-5-hydrazinosulfonyl-benzoesaeure
• Synonyms: 2-Brom-5-hydrazinosulfonyl-benzoesaeure
• CAS NO: 17646-08-1
• Molecular Weight: 295.114
• Mol File: 17646-08-1.mol

Chemical Properties

• CAS DataBase Reference: 2-Brom-5-hydrazinosulfonyl-benzoesaeure(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Brom-5-hydrazinosulfonyl-benzoesaeure(17646-08-1)
• EPA Substance Registry System: 2-Brom-5-hydrazinosulfonyl-benzoesaeure(17646-08-1)

Safety Data

• Hazardous Substances Data: 17646-08-1(Hazardous Substances Data)

Upstream product

• 3285-31-2 2-bromo-5-(chlorosulfonyl)benzoic acid 
• 88-65-3 2-bromobenzoic-acid 

Downstream Products

• 1152496-37-1 2-bromo-5-(isopropylsulfonyl)benzoic acid 
• 1614246-02-4 2'-fluoro-5'-(7-isopropyl-7H-imidazo[4,5-c]pyridazin-4-yl)-4-(isopropylsulfonyl)[1,1'-biphenyl]-2-carbonitrile 
• 1614246-79-5 4-(ethylsulfonyl)-2'-fluoro-5'-((4-methoxybenzyl)oxy)[1,1'-biphenyl]-2-carbonitrile 
• 1614245-84-9 5'-(7-cyclopropyl-7H-imidazo[4,5-c]pyridazin-4-yl)-2'-fluoro-4-(isopropylsulfonyl)-[1,1'-biphenyl]-2-carbonitrile 
• 1614245-77-0 5'-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-4-(ethylsulfonyl)-2'-fluoro-[1,1'-biphenyl]-2-carbonitrile 
• 1614246-82-0 4-(ethylsulfonyl)-2'-fluoro-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1-biphenyl]-2-carbonitrile 
• 1614246-78-4 2-bromo-5-(ethylsulfonyl)benzonitrile 
• 1614246-77-3 2-bromo-5-(ethylsulfonyl)benzamide 
• 1614245-71-4 5'-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-2'-fluoro-4-(isopropylsulfonyl)[1,1'-biphenyl]-2-carbonitrile 
• 1614246-38-6 2-bromo-5-(isopropylsulfonyl)benzonitrile 
• 1614246-37-5 2-bromo-5-(isopropylsulfonyl)benzamide 

Relevant articles and documents

Chemical Compounds

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.